Literature DB >> 2199246

CA 125 and OA 3 as target antigens for immunodiagnosis and immunotherapy in ovarian cancer.

P Kenemans1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2199246     DOI： 10.1016/0028-2243(90)90201-b

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN： 0301-2115            Impact factor:   2.435


× No keyword cloud information.
  5 in total

Review 1.  Prospects of chimeric antigen receptor T cell therapy in ovarian cancer.

Authors:  Vishal Jindal; Ena Arora; Sorab Gupta; Amos Lal; Muhammad Masab; Rashmika Potdar
Journal:  Med Oncol       Date:  2018-04-12       Impact factor: 3.064

Review 2.  Ovarian cancer immunotherapy: opportunities, progresses and challenges.

Authors:  Bei Liu; John Nash; Carolyn Runowicz; Helen Swede; Richard Stevens; Zihai Li
Journal:  J Hematol Oncol       Date:  2010-02-10       Impact factor: 17.388

3.  Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: a comparison of five assays.

Authors:  M R Buist; P Kenemans; G J van Kamp; H J Haisma
Journal:  Cancer Immunol Immunother       Date:  1995-01       Impact factor: 6.968

Review 4.  Targeting AMPK signaling in combating ovarian cancers: opportunities and challenges.

Authors:  Mingo M H Yung; Hextan Y S Ngan; David W Chan
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2016-01-12       Impact factor: 3.848

5.  Distribution of OV-TL 3 and MOv18 in normal and malignant ovarian tissue.

Authors:  M R Buist; C F Molthoff; P Kenemans; C J Meijer
Journal:  J Clin Pathol       Date:  1995-07       Impact factor: 3.411
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.